文献速递甲状腺疾病

远处转移性分化型甲状腺癌伴乳头状组织学中非碘摄取性疾病高度流行

Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该回顾性分析纳入2012至2020年诊断时即有远处转移的分化型甲状腺癌患者78例,首次治疗后扫描48.7%的转移灶无碘摄取。乳头状结构、BRAFV600E突变及BRAFV600E联合TERT启动子突变者阴性扫描率分别为71.1%、80.9%和100%。BRAFV600E样肿瘤阴性扫描率76.9%高于RAS样肿瘤的14.3%(P=.005),且阴性扫描者年龄更大(62.4岁 vs 47.0岁,P=.03)。

要点

  • 诊断时即有远处转移的分化型甲状腺癌患者中,48.7%首次治疗后扫描转移灶无碘摄取。
  • BRAFV600E样肿瘤阴性扫描率76.9%,高于RAS样肿瘤的14.3%(P=.005)。
  • BRAFV600E联合TERT启动子突变的乳头状癌患者阴性扫描率达100%。

核心结论

  • 在诊断时即有远处转移的分化型甲状腺癌患者中,非碘摄取性疾病在BRAFV600E样癌症中高度流行,尤其伴BRAFV600E和TERT启动子突变者,并与年龄较大相关。
  • 作者认为需要更好的策略来改善这些患者的放射性碘治疗反应。

研究设计与样本

  • 回顾性分析2012年至2020年间诊断时即有远处转移的分化型甲状腺癌患者,共78例。
  • 将远处转移灶的碘摄取与肿瘤组织学和突变谱进行相关性分析。
  • 基于癌症基因组图谱的见解,评估BRAFV600E样(BVL)与RAS样(RL)癌症之间碘摄取差异。

主要发现

  • 78例患者中,48.7%首次治疗后扫描显示远处转移灶无碘摄取。
  • 乳头状结构甲状腺乳头状癌、伴BRAFV600E突变的甲状腺乳头状癌、伴BRAFV600E和TERT启动子突变的甲状腺乳头状癌的阴性扫描率分别为71.1%、80.9%和100%。
  • BVL肿瘤与RL肿瘤阴性扫描率分别为76.9%和14.3%(P=.005)。
  • 调整年龄、性别、种族、放射性碘准备方法、骨转移和放射性碘剂量后,BVL肿瘤(伴BVL突变或乳头状结构)阴性摄取比值比为19.8(95%CI,2.72-144),RL肿瘤(伴RL突变或滤泡结构)阴性摄取比值比为0.048(95%CI,0.006-0.344)。
  • 阴性扫描患者年龄显著大于阳性扫描患者(62.4岁 vs 47.0岁,P=.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with radioactive iodine (RAI) refractory metastatic differentiated thyroid cancer (DTC) have poor prognosis. Early identification of RAI refractoriness may improve care. OBJECTIVE: This work aimed to characterize DTC patients with distant metastases (DM) at diagnosis who presented with non-iodine-avid disease. METHODS: Retrospective analyses of DTC patients with DM at diagnosis who presented between 2012 and 2020 were performed. Iodine uptake in DM was correlated with tumor histology and mutational profile. The difference in uptake between BRAFV600E-like (BVL) and RAS-like (RL) cancers based on insights from The Cancer Genome Atlas was evaluated. RESULTS: Among 78 patients, 48.7% had negative uptake in DM on the first posttherapy scan. Negative scans were highly prevalent in papillary thyroid carcinoma (PTC) with papillary architecture, PTC with BRAFV600E mutation, and PTC with both BRAFV600E and TERT promoter mutations (71.1%, 80.9%, and 100%, respectively). BVL and RL tumors exhibited distinct uptake patterns with negative scan prevalence of 76.9% and 14.3% (P = .005). Multivariate logistical regression confirmed high odds of negative uptake in BVL tumors with either BVL mutations or papillary architecture, 19.8 (95% CI, 2.72-144), and low odds of negative uptake in RL tumors with either RL mutations or follicular architecture, 0.048 (95% CI, 0.006-0.344), after adjusting for age, sex, race, RAI preparation method, bone metastases, and RAI dose. Patients with negative scans were significantly older (62.4 vs 47.0 years, P = .03). CONCLUSION: Among DTC patients with DM at diagnosis, non-iodine-avid disease is highly prevalent in patients with BVL cancers, particularly with BRAFV600E and TERT promoter mutations, and is associated with an older age. Better strategies are needed to improve RAI treatment response for these patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Soe MH, Chiang JM, Flavell RR, et al. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology. J Clin Endocrinol Metab. 2022. PMID: 35556126. doi:10.1210/clinem/dgac305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。